Agenus Inc. (NASDAQ:AGEN)’s share price rose 2.5% on Wednesday . The company traded as high as $6.29 and last traded at $6.20, with a volume of 718,687 shares. The stock had previously closed at $6.05.

AGEN has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Agenus in a report on Sunday, July 31st. Jefferies Group upped their price objective on shares of Agenus from $6.00 to $7.00 and gave the company a “buy” rating in a report on Friday, July 29th. Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Agenus in a report on Friday, June 10th. Finally, Zacks Investment Research raised shares of Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Agenus presently has an average rating of “Buy” and an average price target of $10.25.

The company’s market cap is $524.95 million. The firm’s 50 day moving average is $5.43 and its 200 day moving average is $4.21.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The company had revenue of $6.59 million for the quarter, compared to the consensus estimate of $5.12 million. On average, equities analysts predict that Agenus Inc. will post ($1.27) EPS for the current year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.